Evidence map›Paper›PMID 39453729›Full record

ArticleJournal of natural products2024

New Discorhabdin D Analogues from

Maria Orfanoudaki, Masoumeh Dalilian, Lin Du, Cindy H Chau, William D Figg, Barry R O'Keefe, Tanja Grkovic

Abstract read
In one paragraph

Article in Journal of natural products, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Marine natural products.Natural product reports · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maria OrfanoudakiMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21701-1201, United States.ORCID 0000-0002-9409-7645
Masoumeh DalilianMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21701-1201, United States.
Lin DuMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21701-1201, United States.ORCID 0000-0001-8751-4482
Cindy H ChauGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States.
William D FiggGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States.
Barry R O'KeefeMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21701-1201, United States.ORCID 0000-0003-0772-4856
Tanja GrkovicMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21701-1201, United States.ORCID 0000-0002-6537-3997

Funding

Development of Anticancer AgentsZIASC006538 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$8.6M
Intramural NIH HHS ZIA SC006538
6 · The paper itself

Abstract

Chemical profiles of

Indexed as

Drug Screening Assays, AntitumorPoriferaAnimalsAntineoplastic AgentsHumansMolecular StructureNuclear Magnetic Resonance, BiomolecularAntineoplastic Agents

Identifiers

PMID39453729
PMCPMC12327899

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.